goBalto, Inc. Releases New Enhancements to Address Continued Market Momentum Novartis Improves Cycle Times and Gains Process Efficiencies
SAN FRANCISCO, March 13, 2014 /PRNewswire/ -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today updates to its signature software platform. Key enhancements include additional global configuration support and new integration capabilities for smooth enterprise implementation.
The platform's configuration infrastructure allows customers to define and process, out of the box, all of the countries, documents, and submissions required for a study. This 4th-generation release also includes seamless integration into enterprise architectures. Additional enhancements allow for greater collaboration between contract research organizations (CROs) and their partnering organizations.
The new features and functionality strengthen goBalto's commitment to delivering world-class solutions designed with customers in mind. They provide faster setup, easier closeout, enhanced collaboration, and the flexibility of a solution that can mirror any organization's clinical study startup process.
With its platform now serving hundreds of studies in over 40 countries representing thousands of clinical study sites, goBalto is driving change in the study startup space and anticipating customer and industry needs.
As a result of this growing demand, the platform has a new name. Tracker 2.0 is now called Activate™, bringing focus to what the solution does best: guide users through site activation in the fastest and most efficient way possible. Activate is multi-version so that customers can use more than one version simultaneously, and new iterations can be created more quickly.
goBalto CEO Sujay Jadhav stated, "We continue to experience strong demand for our solution. With this latest release, we're enhancing our global support and ability to meet enterprise needs more holistically. Our customers are experiencing strong business benefits; with these enhancements to Activate, we've further solidified our position as a leader in study startup."
"We wanted a superior solution to differentiate our study startup operations so we chose goBalto," said Barry Milton, Director Project Management Planning and Regulatory Document Management, Novartis Pharmaceuticals Corporation. "The solution will enable us to drive a consistent, dynamic process across our studies, while improving cycle times and other key metrics."
goBalto develops next-generation solutions that simplify how clinical trials are started in the pharmaceutical, biotechnology, and medical device industries. Our flagship product, Activate, is a purpose-built software-as-a-service clinical research platform. It enables clinical trial sponsors and research organizations to track milestones on the critical path, and provides document workflow management capabilities in a transparent, regulatory-compliant, and user-friendly way. Founded in 2008 in Silicon Valley by biotechnology industry veteran Jae Chung, goBalto is backed by leading health technology investors. For more information, visit www.gobalto.com.
SOURCE goBalto, Inc.